In The News

Press Release

Nicole Rogas, Senior Vice President at Experian Health, joins Nuevozen Advisory Board

Nicole Rogas

Nuevozen Corp., a Silicon Valley based Healthcare technology company developing predictive screening and diagnostic solution using AI/ML for cancer, is pleased to announce the addition of Nicole Rogas, Senior VP of Sales and Client Success at Experian Health, to the company’s Advisory Board.

I am very pleased to have Nicole Rogas as part of our advisory board,” stated Karan Aujla, Nuevozen’ chief executive officer. “As a senior executive in healthcare industry, Nicole has had tremendous success developing high performance teams and a differentiated client base to propel growth in her business. I look forward to working with her to leverage her experiences in healthcare industry”

“I’m truly excited to join Nuevozen’ advisory board and look forward to partnering with the executive team to provide insight on how we can extend the reach and visibility of the work the team is doing…..,” said Nicole Rogas “I believe that Nuevozen’s AI/ML technology can make a significant impact on society with earlier and more accurate breast cancer diagnosis but also through providing access to healthcare screening via AI to areas of our world that otherwise would not have access to care.”

 

Nicole Rogas will provide guidance and advice on Nuevozen’ sales and go to market strategies. As Senior Vice President of Sales & Client Success, Nicole is responsible for leading Experian Health’s teams focused on protecting and driving growth through all healthcare channels including hospitals, physicians, payers, labs, and pharmacies.  In addition to Sales, Nicole is also responsible for Strategic Channel Partnerships, the Pre-Sales/Sales Engineering team, the Account Management organization and the Sales Operation’s organization focused on sales reporting, sales enablement and training.

 

About Nuevozen Corp.

Founded in 2018, Nuevozen Corp. is a privately held Healthcare technology company located in San Francisco Bay Area. Nuevozen’ mission is to help healthcare providers in improving quality and speed of care For more information, contact info@Nuevozen.com or visit Nuevozen.com.

 

Media Contact:
Nuevozen Corp.
Karan Aujla

CEO & Co-Founder

karan@nuevozen.com

Featured Post

Dr. Victor Levin, founding member of the Society of Neuro-Oncology, joins Nuevozen’ Medical Advisory Board

Nuevozen, Inc. a San Francisco based Healthcare Artificial Intelligence company developing patient risk assessment and diagnostic solution for cancer and other serious diseases, is pleased to announce the addition of Dr. Victor Levin, a leading Neuro Oncologist in the world, to the company’s medical advisory board.

Currently, Dr. Levin is a Neuro-Oncology Physician in the Department of Neurosurgery and Neuroscience, Kaiser Permanente Medical Center, Redwood City. He is also Professor Emeritus, Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center and Clinical Professor, Department of Neurosurgery, at UCSF School of Medicine. He built and chaired the world-renowned Neuro-Oncology program at the University of Texas M. D. Anderson Cancer Center.

I am deeply honored and excited to have Dr. Levin, one of the leading experts in the field of neuro-oncology, join our advisory board,” stated Karan Aujla, Nuevozen’ co-founder and CEO. “I look forward to working with Dr Levin to leverage his knowledge and expertise and his passion for improving patient outcome to help our team identify and develop clinical use cases of AI including volumetric analysis of infiltrative CNS tumors seen with MRI”.

“I’m excited to join Nuevozen’ advisory board and look forward to helping guide the company as they continue to develop their Artificial Intelligence technology,” said Dr. Victor Levin. “I believe that Artificial Intelligence has the potential to improve the diagnosis of infiltrative CNS tumors and metastases and to quantify benefit of new drug therapies and other treatments for CNS tumors”

 

Dr. Levin founded the Society for Neuro-Oncology in 1995 and served as its first president in 1996. He has published nearly 400 peer-reviewed articles, chapters, editorials, and books including the multidisciplinary textbook, Cancer in the Nervous System. In his career, Dr. Levin received numerous awards including the Anne and Jason Farber Award for Neuro-Oncology, Gold Medal Award for Extraordinary Achievement (Society for Neuro-Oncology).  He has also been listed in The Best Doctors in America, America’s Top Doctors in Cancer, and America’s Top Doctors for many years. 

 

About Nuevozen Corp.

Founded in 2018, Nuevozen Corp. is a privately held Healthcare AI company located in San Francisco Bay area. Nuevozen’ mission is to help healthcare providers in improving quality and speed of care by utilizing artificial intelligence.

Media Contact:
Karan Aujla

info@Nuevozen.com

Featured Post

Dr. Rajan Jain, Professor of Radiology and Neurosurgery at NYU Langone Health, Joins Nuevozen’s Medical Advisory Board

 

Dr. Rajan Jain

Nuevozen Corp., a San Francisco based Healthcare Artificial Intelligence company developing patient risk assessment and diagnostic solution for cancer and other serious diseases, is pleased to announce the addition of Dr. Rajan Jain, Professor of Radiology and Neurosurgery at NYU Langone Health, to the company’s medical advisory board.

 

We are deeply honored to have Dr. Jain join our advisory board,” stated Karan Aujla, Nuevozen’ co-founder and CEO. “We look forward to leveraging Dr. Jain’s extensive background and experience in Brain tumor imaging and genomics as we move forward with developing a comprehensive AI platform for cancer screening and diagnosis”.

 

“I’m truly excited to join Nuevozen’ advisory board and look forward to collaborating with the other key neuro-oncology opinion leaders to help guide the company as they continue to develop their Artificial Intelligence technology,” said Dr. Rajan Jain. “I believe that Artificial Intelligence has the potential to assist Radiologists like me in improving the diagnosis and prognosis of cancer.”

 

Dr. Jain will provide guidance and advice on Nuevozen’ AI work in the field of Brain tumor imaging. His research interest includes brain tumor imaging, imaging genomics, tumor angiogenesis, perfusion imaging and brain tumor treatment effects. He has published over 150+ papers during the last 20 years in the field of Brain Neoplasms, MRI, Gliomo, Glioblastoma, Tomography and AI. Dr. Jain completed his fellowships from the Vancouver General Hospital and University of Michigan Hospital. He is board certified in Neuroradiology and Diagnostic Radiology.

 

About Nuevozen Corp.

Founded in 2018, Nuevozen Corp. is a privately held Healthcare AI company located in San Francisco Bay area. Nuevozen’ mission is to help healthcare providers in improving quality and speed of care by utilizing artificial intelligence. 

 

For more information, email info@Nuevozen.com or visit Nuevozen.com.

 

Media Contact:

Nuevozen Corp.
Karan Aujla

CEO & Co-Founder

karan@nuevozen.com

 

Featured Post

Fourth Terrace Diagnostic Centre partners with Nuevozen Corp to develop and deploy an Artificial Intelligence (AI) powered Breast Cancer Diagnostic and risk prediction solution

May 23, 2019

Nassau, Bahamas – (May 21, 2019) – Nuevozen Corporation, a leading provider of innovative cancer detection solutions is pleased to announce their partnership with Fourth Terrace Diagnostic Centre in the development and installation of our Artificial Intelligence powered Breast cancer solution at Fourth Terrance Diagnostic Centre, a leading diagnostic Centre in The Bahamas. This AI-based solution is being developed to assist Radiologists in the diagnosis and identification of women’s individual risk of developing breast cancer.

The Bahamas ranks among the top 20 countries in the world in terms of the number of women per capita with breast cancer. The breast cancer incidence rate (IR) for females in the Bahamas is increasing and 48% of the Bahamian patients diagnosed with breast cancer are less than 50 years of age and are diagnosed at Stage III. Three different genes influencing breast cancer have been identified in Bahamian women making it a country with one of the highest proportion of mutations in the world, and approximately 24 percent of the women with breast cancer in The Bahamas has one of these mutations. There are also many other risks factors that are still not well understood.

Fourth Terrace Diagnostic Centre’s founder, CEO and Lead Radiologist, Dr. C. Elizabeth Darville MBBS, FRCP, has been at the forefront of cancer care in the Bahamas for more than 35 years. She has promoted screening from earlier ages for Bahamian women and has seen the benefit of early diagnosis for her patients.

“If Nuevozen’s AI solution can assist our radiologists in improving breast cancer diagnosis, we can improve patient outcome through early detection” said Dr. Darville, “Also if an AI solution is able to predict individual Bahamian women’s risk of developing breast cancer, we will be able to move from age-based screening to risk-based screening, and this will dramatically improve early detection and survival.” “We are pleased to announce that Dr. Vijay Anand Subramanian, who has been a part of our team for many years, has been appointed as the Director of our Artificial Intelligence Research and Development Department.

Fourth Terrace Diagnostic Centre’s President, Mr. Stanley Darville explained that, “Technological advances in medicine continue to occur at almost an exponential pace and Fourth Terrace Diagnostic Centre is working closely with our local Bahamian IT firm Redstone Technologies to provide the high level of support for our Data Centre and the immense computing power that is needed to implement Nuevozen’s Artificial Intelligence solution.”

“We are extremely excited to be working with FTDC.” said Karan Aujla, co-founder and CEO of Nuevozen, “Current risk models are population-based and these risk models don’t apply to Bahamian women due to the high incidence of genetic mutations, and available data has shown that by using the genetic information together with and the information available in the DICOM images and the patient history, we can come up with a more accurate risk assessment. I believe that by analyzing patient data using AI techniques we can help healthcare providers in improving the prevention and treatment of breast cancer.”

Media Inquiries:

Nuevozen Corp.                                                                                                         Fourth Terrace Diagnostic Centre

info@nuevozen.com                                                                                                 info@ftdcimaging.com

Featured Post

Media

Featured Post
Featured Post
Featured Post
Featured Post